28190392|t|PI3K / Akt pathway: a potential therapeutic target for chronic pain
28190392|a|Chronic pain is among the most disabling and costly disorders, with prevalence ranging from 10% to 55%. However, current therapeutic strategies for chronic pain are unsatisfactory due to our poor understanding of its mechanisms. Thus, novel therapeutic targets need to be found in order to improve these patients' quality of life. PI3K and its downstream Akt are widely expressed in the spinal cord, particularly in the laminae I-IV of the dorsal horn, where nociceptive C and Aδ fibers of primary afferents principally terminate. Recent studies have demonstrated their critical roles in the development and maintenance of chronic pain. In this review, we summarized the roles and mechanisms of PI3K / Akt pathway in the progression of chronic pain through sciatic nerve injury, diabetic neuropathy, spinal cord injury, bone cancer, opioid tolerance, or opioid - induced hyperalgesia.
28190392	0	4	PI3K	T116,T126	C0044602
28190392	7	10	Akt	T116,T126	C0164786
28190392	11	18	pathway	T044	C0037080
28190392	32	43	therapeutic	T169	C0302350
28190392	44	50	target	T169	C1521840
28190392	55	67	chronic pain	T184	C0150055
28190392	68	80	Chronic pain	T184	C0150055
28190392	99	108	disabling	T047	C0596452
28190392	120	129	disorders	T047	C0012634
28190392	136	146	prevalence	T081	C0683921
28190392	147	154	ranging	T081	C1514721
28190392	189	200	therapeutic	T169	C0302350
28190392	216	228	chronic pain	T184	C0150055
28190392	233	247	unsatisfactory	T080	C0439856
28190392	259	263	poor	T080	C0542537
28190392	264	277	understanding	T041	C0162340
28190392	285	295	mechanisms	T169	C0441712
28190392	309	320	therapeutic	T169	C0302350
28190392	321	328	targets	T169	C1521840
28190392	358	365	improve	T033	C0184511
28190392	372	381	patients'	T101	C0030705
28190392	382	397	quality of life	T078	C0034380
28190392	399	403	PI3K	T116,T126	C0044602
28190392	412	422	downstream	T082	C0522506
28190392	423	426	Akt	T116,T126	C0164786
28190392	438	447	expressed	T045	C1171362
28190392	455	466	spinal cord	T023	C0037925
28190392	488	500	laminae I-IV	T023	C2340386
28190392	508	519	dorsal horn	T023	C0228575
28190392	527	540	nociceptive C	T026	C0501409
28190392	545	554	Aδ fibers	T026	C0027750
28190392	558	565	primary	T080	C0205225
28190392	566	575	afferents	T023	C0206309
28190392	588	597	terminate	T079	C2746065
28190392	606	613	studies	T062	C0008972
28190392	638	646	critical	T080	C1511545
28190392	647	652	roles	T077	C1705810
28190392	660	671	development	T169	C1527148
28190392	676	687	maintenance	T052	C0024501
28190392	691	703	chronic pain	T184	C0150055
28190392	713	719	review	T170	C0282443
28190392	739	744	roles	T077	C1705810
28190392	749	759	mechanisms	T169	C0441712
28190392	763	767	PI3K	T116,T126	C0044602
28190392	770	773	Akt	T116,T126	C0164786
28190392	774	781	pathway	T044	C0037080
28190392	789	800	progression	T046	C0242656
28190392	804	816	chronic pain	T184	C0150055
28190392	825	845	sciatic nerve injury	T037	C0161467
28190392	847	866	diabetic neuropathy	T047	C0011882
28190392	868	886	spinal cord injury	T037	C0037929
28190392	888	899	bone cancer	T191	C0279530
28190392	901	917	opioid tolerance	UnknownType	C0240601
28190392	922	928	opioid	T109,T121,T131	C0242402
28190392	931	938	induced	T169	C0205263
28190392	939	951	hyperalgesia	T184	C0020429